EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieStudienprotokollOpen Access · CC BY 4.0

Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study

Karlien Mul iD, Kate Eichinger, Man Hung, Valeria A Sansone, Cynthia Gagnon, Sub Subramony, Richard H Roxburgh, Johanna Hamel, Jeffrey M Statland, Bakri Elsheikh, Chris Turner, Jacinda Sampson und 15 weitere

PLOS One · 11.12.2025 · 20 (12) · e0331163

DOI: 10.1371/journal.pone.0331163 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS One, online erschienen am 11.12.2025. Verfasst von Karlien Mul und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Myotonic Dystrophy, Biomarkers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Food and Drug Administration, Myotonic Dystrophy Foundation, Avidity Biosciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myotonic dystrophy type 1 (DM1) is an autosomal dominant inherited multi-system disorder that affects skeletal muscles but also many other organ systems. Molecular targets have been identified and targeted therapies are being developed and tested in first-in-human clinical trials. However, insufficient knowledge of the phenotypic heterogeneity and natural course of the disease, together with a lack of reliable biomarkers, complicate the design of clinical trials.

Methods

The main objectives of this study are to 1) characterize the phenotypic heterogeneity and disease progression of DM1 in a large cohort; 2) identify baseline characteristics that predict subsequent progression; 3) validate RNA biomarkers of disease severity. This is a prospective, multi-site observational study with a follow-up period of 24 months including approximately 700 adult DM1 patients. Visits will occur at baseline, and months 12 and 24. All patients will undergo strength testing, myotonia assessment, a battery of functional outcome assessments, spirometry, and complete various questionnaires and cognitive tests. Blood and urine samples will be taken at each visit for biomarker studies. A subset of 60 patients will undergo a muscle biopsy at baseline and at an additional 3-month visit. The sensitivity to disease progression and minimally clinically important differences will be determined for the various clinical outcome measures. Associations between baseline patient characteristics and the rate of disease progression will be evaluated.

Discussion

The results of this large international study on DM1 will contribute to optimizing clinical trial design. Both data and biological samples will be collected for future research as well.

Trial registration

Clinicaltrials.gov NCT03981575

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myotonic DystrophyBiomarkersHumansAdultDisease ProgressionProspective StudiesFemaleMaleMiddle Aged

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Neurology, University of Rochester Medical Center, Rochester, New York, United States of America.
  • Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, United States of America.
  • Neurorehabilitation Unit, The NeMO Clinical Center, University of Milan, Milan, Italy.
  • Department of Neurology, Université de Sherbrooke, CIUSSS Saguenay-Lac-Saint-Jean, Québec, Canada.
  • Department of Neurology, University of Florida College of Medicine, Gainesville, Florida, United States of America.

ORCID-Profile: Karlien Mul, Benedikt Schoser, Ericka P Greene

Förderung

  • U.S. Food and Drug Administration
  • Myotonic Dystrophy Foundation
  • Avidity Biosciences
  • Dyne Therapeutics
  • Vertex Pharmaceuticals
  • Takeda Pharmaceuticals U.S.A.
  • PepGen Inc
  • Sanofi Genzyme

Zitieren

APA

Mul, K., Eichinger, K., Hung, M., Sansone, V. A., Gagnon, C., Subramony, S., Roxburgh, R. H., Hamel, J., Statland, J. M., Elsheikh, B., Turner, C., Sampson, J., Ragole, T., Matthews, E., Schoser, B., Swenson, A., Laverty, C., Shieh, P., Greene, E. P., …, & Myotonic Dystrophy Clinical Research Network (2025). Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study. PLOS One, 20(12), e0331163. https://doi.org/10.1371/journal.pone.0331163

Vancouver

Mul K, Eichinger K, Hung M, Sansone VA, Gagnon C, Subramony S, et al. Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study. PLOS One. 2025;20(12):e0331163. doi:10.1371/journal.pone.0331163

BibTeX
@article{Mul2025,
  author = {Mul, Karlien and Eichinger, Kate and Hung, Man and Sansone, Valeria A and Gagnon, Cynthia and Subramony, Sub and Roxburgh, Richard H and Hamel, Johanna and Statland, Jeffrey M and Elsheikh, Bakri and Turner, Chris and Sampson, Jacinda and Ragole, Thomas and Matthews, Emma and Schoser, Benedikt and Swenson, Andrea and Laverty, Chamindra and Shieh, Perry and Greene, Ericka P and Takahashi, Masanori and Wicklund, Matthew and Dekdebrun, Jeanne and Raymond, Jennifer and DeSpain, Erin and Thornton, Charles A and Johnson, Nicholas E and Myotonic Dystrophy Clinical Research Network, Myotonic Dystrophy Clinical Research Network},
  title = {Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {12},
  pages = {e0331163},
  doi = {10.1371/journal.pone.0331163}
}
Kostenlos starten →